Financial Performance - The company reported a net loss of 3.11millionforthethreemonthsendedDecember31,2024,comparedtoanetlossof1.31 million for the same period in 2023, indicating an increase in losses of approximately 137%[19] - The company’s accumulated deficit increased to 20.55millionasofDecember31,2024,comparedto17.43 million at the end of the previous quarter[32] - The company has incurred accumulated net losses of 20,547,143sinceinceptionthroughDecember31,2024,withnorevenuesgeneratedtodate[130]−ThecompanyhasnotgeneratedanyrevenuefromitsinceptionthroughDecember31,2024[143]−Thecompanyreportedanetlossof3,113,362 for the three months ended December 31, 2024, compared to a net loss of 1,313,945forthesameperiodin2023[158]AssetsandEquity−AsofDecember31,2024,thetotalassetsofNanoNuclearEnergyInc.increasedto134.14 million, up from 35.10millionasofSeptember30,2024,representingagrowthofapproximately282130.06 million as of December 31, 2024, up from 31.61millionasofSeptember30,2024,representinganincreaseofapproximately311123.27 million as of December 31, 2024, compared to 28.51millionattheendofthepreviousquarter,markinganincreaseofapproximately332125.93 million as of December 31, 2024, compared to 27.50millionatSeptember30,2024,reflectingagrowthofapproximately357101.40 million from common stock issuances during the three months ended December 31, 2024[25] - The Company received 2,106,437insubscriptionsaspartoftheSeriesBRoundofprivatefinancing,whichbeganinDecember2023andendedinJanuary2024[70]−TheCompanycompletedanIPOonMay7,2024,issuing2,562,500sharesat4.00 per share, generating net proceeds of approximately 9.0million[71]−TheunderwriterfullyexercisedtheIPOOver−AllotmentOption,resultinginadditionalgrossproceedsof1,537,500 and net proceeds of approximately 1.4million[72]−TheJuly2024Follow−onOfferingraisedapproximately16.1 million in net proceeds from the sale of 900,000 units at an offering price of 20.00perunit[73]−TheCompanygeneratedapproximately2.5 million in net proceeds from the full exercise of the July 2024 Follow-on Over-Allotment Option[74] - The October 2024 Follow-on Offering produced net proceeds of approximately 32.3millionfromthesaleof2,117,646unitsatanofferingpriceof17.00 per unit[76] - The Company received net proceeds of approximately 55.1millionfromtheNovember2024PrivatePlacement,selling2,500,002sharesatacombinedpurchasepriceof24.00 per share[77] Research and Development - Research and development expenses for the three months ended December 31, 2024, were 904,923,comparedto520,016 for the same period in 2023, reflecting an increase of approximately 74%[19] - The company is developing advanced nuclear microreactors, including ZEUS and ODIN, targeting various sectors such as data centers and military applications[28] - The company plans to invest approximately 40millionoverthenexttwelvemonths,with25 million allocated for microreactor development and testing[126] - The microreactor demonstration work is estimated to occur between 2025 and 2027, with licensing applications processed between 2026 and 2029[127] - The company is in the pre-revenue stage, focusing on developing advanced nuclear microreactors, with a goal to commercially launch one product by 2030-2031[113] Legal and Regulatory Matters - The company is currently involved in legal proceedings, including a putative securities class action lawsuit filed on August 9, 2024[173] - The company anticipates significant expenditures in defending its products and against claims of intellectual property infringement in the future[176] - The company expects to maintain a full valuation allowance on its deferred tax assets until an appropriate level of profitability is attained[62] Operational Expenses - General and administrative expenses increased by 1,665,674,or2012,494,570 for the three months ended December 31, 2024, compared to 828,896forthesameperiodin2023[147]−Negativeoperatingcashoutflowswere3,242,526 for the three months ended December 31, 2024, compared to 1,106,733forthesameperiodin2023[151]−NetcashusedinoperatingactivitiesforthethreemonthsendedDecember31,2024,was3,242,526, an increase of 2,135,793comparedto1,106,733 for the same period in 2023[158][159] - Net cash used in investing activities for the three months ended December 31, 2024, was 3,560,000,relatedtodepositsfortheacquisitionofUSNCAssets[160]AcquisitionsandInvestments−ThecompanyacquiredALIPtechnologyforapproximately1.67 million, which includes cash and common stock considerations, and anticipates completion of the SBIR Phase III project by June 21, 2025[97][99] - The company invested 2,000,000inLISTechnologiesInc.aspartofan11.88 million seed funding round to support the development of advanced laser enrichment technology[100] - The company entered into an asset purchase agreement to acquire USNC's nuclear energy technology assets for 8.5million,withadepositof3.56 million already provided[105] - The company closed an asset acquisition of the KRONOS MMR Energy System and LOKI MMR for 8.5million,includingcontractsandintellectualpropertyrights[116]−Theacquisitionincluded38patentsandfivecontractswiththird−partycollaborators,enhancingthecompany′sintellectualpropertyportfolio[118]LeaseObligations−TheCompanyhadonelong−termoperatingleaseasofDecember31,2024,consistentwiththepreviousreportingperiod[47]−Thecompanyhasalong−termoperatingleaseliabilityof1,891,400 as of December 31, 2024, with future minimum lease payments totaling 2,832,025[95]−Thecompanyreportedaleasecostof104,398 for the three months ended December 31, 2024, with cash paid for operating leases amounting to 100,815[94]−Thecompanyhasaweighted−averagediscountrateof13.533,605, with a lease term ending on July 31, 2031[164] - A new lease for a demonstration facility in Westchester County, New York, was entered into in January 2025, costing $17,000 per month, with a lease term ending on December 31, 2030[165]